Drug intelligence / Profile preview

Lactiplantibacillus plantarum SKO-001

Development stage: Preclinical
Lead developer: Kolmar BNH
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactiplantibacillus plantarum SKO-001 is a probiotic bacterial strain isolated from the root of Korean angelica (*Angelica gigas*). [3, 7] It is being developed by Kolmar BNH as a dietary supplement for weight management. [1, 2] A 12-week, randomized, double-blind, placebo-controlled clinical trial involving 100 overweight adults demonstrated that a daily dose of 20 billion colony-forming units (CFU) in a capsule form led to a significant reduction in body fat percentage and fat mass compared to a placebo. [1, 2, 7] In addition to reducing body fat, the supplement was also found to significantly decrease LDL cholesterol and the hormone leptin, while increasing levels of adiponectin. [1, 2, 7] The anti-obesity effects are believed to be mediated through the modulation of the gut microbiome, which in turn influences lipid metabolism and adipogenesis by downregulating genes such as SREBP-1c, PPAR-γ, and C/EBPα. [2] The clinical trial was funded by its manufacturer, Kolmar BNH. [1, 2]

Beyond the preview

Go deeper on Lactiplantibacillus plantarum SKO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactiplantibacillus plantarum SKO-001.

Explore the full profile